Last reviewed · How we verify

avutometinib and sotorasib

Verastem, Inc. · Phase 1 active Small molecule

avutometinib and sotorasib is a Small molecule drug developed by Verastem, Inc.. It is currently in Phase 1 development. Also known as: AMG 510, LUMAKRAS™, VS-6766.

At a glance

Generic nameavutometinib and sotorasib
Also known asAMG 510, LUMAKRAS™, VS-6766
SponsorVerastem, Inc.
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about avutometinib and sotorasib

What is avutometinib and sotorasib?

avutometinib and sotorasib is a Small molecule drug developed by Verastem, Inc..

Who makes avutometinib and sotorasib?

avutometinib and sotorasib is developed by Verastem, Inc. (see full Verastem, Inc. pipeline at /company/verastem-inc).

Is avutometinib and sotorasib also known as anything else?

avutometinib and sotorasib is also known as AMG 510, LUMAKRAS™, VS-6766.

What development phase is avutometinib and sotorasib in?

avutometinib and sotorasib is in Phase 1.

Related